Patients with Type II diabetes fared better with Medtronic‘s (NYSE:MDT)MiniMed Paradigm Veo insulin pumps that with multiple daily injections, according to a Medtronic-backed study published in the journal Diabetes, Obesity & Metabolism.
Fridley, Minn.-based Medtronic said the 331-patient Opt2mise clinical trial compared the MDI cohort with the MiniMed-treated group; after 6 months, the MDI cohort was moved to the MiniMed arm; at 12 months, the group that moved to the insulin pump arm doubled the A1C measurement for glucose control and used 19% less insulin.
The group treated with MiniMed for the entire 12 months showed a further 0.1% AC1 reduction to a full-year value of 7.8%, Medtronic said.
“The demonstration in a randomized controlled trial of the durability of the glycemic control obtained with pump therapy should be emphasized. Earlier randomized controlled trials were too brief to offer insights into durability of response, although observational studies have consistently shown a durable response lasting up to 1 year and more. Three large French observational surveys of patients with poorly controlled Type II diabetes each showed a significant improvement in [A1C] (1.2–1.7%), which was subsequently maintained during long-term follow-up. The Opt2mise study complements and extends these findings by showing the sustained superiority of pump therapy over MDI treatment in a similar patient population,” the researchers wrote in the DOM journal.
“At Medtronic Diabetes, we are looking at how we can deliver greater freedom and better health for all people with diabetes, including those living with Type II,” vice president Dr. Francine Kaufman said in prepared remarks. “The results of the Opt2mise trial, which is the largest study of its kind, will help us expand access to insulin pump therapy as a standard of care treatment for the growing number of insulin-takingType II diabetes patients so they can enjoy improved clinical outcomes.”
“The continuation phase of Opt2mise builds on the findings of the initial study period, which showed that insulin pumps helped participants with insulin-requiringType II diabetes safely achieve better glucose control, with lower insulin doses, than MDI,” added lead author Dr. Ronnie Aronson of Toronto’s LMC Diabetes & Endocrinology. “We found that participants who switched from MDI to insulin pumps were able to achieve these same results by the 12-month mark. Given that many patients with type 2 diabetes have difficulty achieving glycemic control, these additional data demonstrate that insulin pumps provide a significant advantage over MDI with a safe and consistent effect.”
